HBIO · Harvard Bioscience Inc
Market Cap
$37.01M
Shares
4.55M
Volume · Oct 8
18.16K
Avg daily vol (3M)
17.73K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.50
Open$8.43
Day$8.43–8.60
52W close$3.80–8.56
Avg vol 30d19K
Short int48K · 1.1% float · 2.6d
Short vol38%
Last earningsAug 11, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 8, 2026
Est · unconfirmed
· in 4 wks
filed Aug 11, 2026
call held Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$87.81M
Trailing 12 months
Net income (TTM)
−$10.41M
Trailing 12 months
Revenue growth YoY
+11.1%
Year over year
Operating margin
-0.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-2.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$30.18M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.2%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.1%
Latest settlement · 2.6 days to cover
AI Brief
Q2 FY26 earnings call · Aug 11, 2026
Q2 FY26
TL;DR. Harvard Bioscience reported Q2 2026 revenue of $22.7 million, up 11% year-over-year, driven by CMT and preclinical demand and strong China sales, and raised full-year 2026 revenue growth guidance to 3%-5% (from 2%-4%) while lowering its adjusted gross margin range to 57%-59% (from 58%-60%) due to product and geographic mix.
Bullish
- + Q2 revenue grew 11% year-over-year to $22.7 million, exceeding guidance, driven by CRO demand and CMT/telemetry strength.
- + Full-year 2026 revenue growth guidance was raised to 3%-5% from 2%-4%.
- + NPI revenue contribution rose to 11% of revenue versus 3% a year ago, and recurring revenue reached 55% of total revenue.
- + Project Viking footprint consolidation is on track, with $3 million in expected 2027 cost savings and $4 million annually thereafter.
Bearish
- − Full-year 2026 adjusted gross margin guidance was lowered by 100 bps to 57%-59% from 58%-60% on unfavorable product and geographic mix.
- − Q2 GAAP gross margin declined to 55.6% from 56.4% in Q2 2025, and adjusted gross margin fell to 56.7% from 57.2%, due to higher CMT and China sales.
- − Q2 net loss widened to ($2.9) million from ($2.3) million, and adjusted EPS deteriorated to ($0.14) from ($0.05).
- − Operating cash flow swung to ($0.3) million used in the first half from $5.7 million generated a year ago, on inventory builds and higher interest costs.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.63
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+35%
above
Price vs 50-day avg
+13%
above
RSI (14)
70
overbought
MACD trend
Positive
52-week position
99%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+7%
trailing
6-month return
+44%
trailing
YTD return
+27%
this year
Relative strength
+33%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.06% of float · ▼ -0.8% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
37 holders — near 3-yr low, contrarian setup
Squeeze score
45
elevated · 0–100
Fundamentals
Revenue growth
−4%
Y/Y
Gross margin
43%
contracting
EPS growth
−357%
Y/Y
Free cash flow
$5.5M
Balance sheet
$27.3M
net debt
Quant / Vol
risk profile
Volatility
88%
annualized · 1-yr
Max drawdown
−45%
past year
ATR
2.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 11, 2026
Adjusted gross margin
· full year
Non-GAAP
57% – 59%
Adjusted EBITDA growth
· full year
Non-GAAP
6% – 10%
Prior guidance
period ended
· from the Earnings Call filed Aug 11, 2026
Adjusted gross margin
· third quarter
56% – 58%
Guided vs delivered
· last 2 settled
Revenues
full year 2024
guided $97M – $102M
$94.14M
Miss −5.4%
Revenues
full year 2023
guided $116M – $120M
$112.25M
Miss −4.9%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+35%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
70
Bearish
MACD trend
Positive
Bullish
52-week position
99%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.06% of float · ▼ -0.8% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
37 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $4
Now $9 · 99%
Range high $9
vs 200-day avg +35%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $2.4M | Six months ended June 30, 2026 | — |
| Adjusted EBITDA margin non-GAAP | 5.6% | Six Months Ended June 30, 2026 | — |
| Adjusted gross margin non-GAAP | 58.3% | Six months ended June 30, 2026 | — |
| Adjusted operating margin non-GAAP | 3.1% | Six months ended June 30, 2026 | — |
| Gross margin | 55.6% | three months ended June 30, 2026 filing | — |
| Net debt | $33.5M | June 30, 2026 | — |
| Non-GAAP gross profit non-GAAP | $25.34M | Six Months Ended June 30, 2026 | — |
| Revenue on a constant currency basis non-GAAP | $42.69M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HBIO
this stock
Harvard Bioscience Inc
|
$37.01M | — | -3.8% | — | 1.1% |
|
ISRG
Intuitive Surgical Inc
|
$146.76B | -26.8% | +20.5% | 47.7 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.07B | — | +8.2% | — | 4.2% |
|
MDLN
Medline Inc.
|
$46.99B | -15.6% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.60B | -6.2% | +13.4% | 21.7 | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HBIO | +7.3% | +6.9% | +43.8% | +7.3% | +26.9% |
| SPY | +1.9% | +1.9% | +10.8% | +1.9% | +14.0% |
| vs SPY | +5.4% | +5.0% | +33.1% | +5.4% | +12.9% |